UROLOGIE PRO PRAXI / Urol. praxi. 2023;24(4):217-220 / www.urologiepropraxi.cz 220 PŘEHLEDOVÉ ČLÁNKY Zvýšenie presnosti diagnostiky karcinómu prostaty glykoprofiláciou vybraných sérových onkomarkerov: klinický a ekonomický dopad na pacienta LITERATÚRA 1. Dale W, Bilir P, Han M, et al. The role of anxiety in prostate carcinoma: a structured review of the literature. Cancer. 2005;104(3):467-478. doi:10.1002/cncr.21198. 2. Bernal-Soriano MC, Parker LA, López-Garrigos M, et al. Factors associated with false negative and false positive results of prostate-specific antigen (PSA) and the impact on patient health: Cohort study protocol. Medicine. 2019;98(40):e17451. doi:10.1097/MD.0000000000017451. 3. Perera M, Manning T, Finelli A, et al. Management of men with previous negative prostate biopsy. Curr. Opin. Urol. 2016;26(5):481-487. doi:10.1097/MOU.0000000000000315. 4. Dimmen M, Vlatkovic L, Hole KH, et al. Transperineal prostate biopsy detects significant cancer in patients with elevated prostate-specific antigen (PSA) levels and previous negative transrectal biopsies. BJU Int. 2012;110(2 Pt 2):E69-E75. doi:10.1111/j.1464-410X.2011.10759.x. 5. Heidrich I, Ačkar L, Mossahebi Mohammadi P, et al. Liquid biopsies: Potential and challenges. Int. J. Cancer. 2021;148(3):528-545. doi:10.1002/ijc.33217. 6. Available from: https://gco.iarc.fr/. 7. Haythorn MR, Ablin RJ. Prostate-specific antigen testing across the spectrum of prostate cancer. Biomark. Med. 2011;5(4):515-526. doi:10.2217/bmm.11.53. 8. Tkac J, Bertok T, Hires M, et al. Glycomics of prostate cancer: updates. Expert Rev. Proteomics. 2019;16(1):65-76. doi:10.1080/14789450.2019.1549993. 9. Petrosyan A. Onco-Golgi: Is Fragmentation a Gate to Cancer Progression? Biochem Mol Biol J. 2015;1(1):16. doi:10.21767/2471-8084.100006. 10. Bertok T, Jane E, Chrenekova N, et al. Analysis of serum glycome by lectin microarrays for prostate cancer patients - a search for aberrant glycoforms. Glycoconj. J. 2020;37(6):703711. doi:10.1007/s10719-020-09958-4. 11. Available from: https://patentscope.wipo.int/search/en/ detail.jsf?docId=WO2019185515. 12. Tkac J, Gajdosova V, Hroncekova S, et al. Prostate-specific antigen glycoprofiling as diagnostic and prognostic biomarker of prostate cancer. Interf. Focus, 2019;9(2). doi. org/10.1098/rsfs.2018.0077. 13. Chen Z, Gulzar ZG, St. Hill CA, et al. Increased expression of GCNT1 is associated with altered O-glycosylation of PSA, PAP, and MUC1 in human prostate cancers. Prostate, 2014;74: 1059-1067. doi.org/10.1002/pros.22826. 14. Bertok T, Jane E, Bertokova A, et al. Validating fPSA Glycoprofile as a Prostate Cancer Biomarker to Avoid Unnecessary Biopsies and Re-Biopsies. Cancers. 2020;12(10):2988. doi:10.3390/cancers12102988. 15. Bertokova A, Bertok T, Jane E, et al. Detection of N, N-diacetyllactosamine (LacdiNAc) containing free prostate-specific antigen for early-stage prostate cancer diagnostics and for identification of castration-resistant prostate cancer patients. Bioorg. Med. Chem. 2021;39:116156. doi:10.1016/j. bmc.2021.116156. 16. Liu MC, Oxnard GR, Klein EA, et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann. Oncol. 2020;31(6):745-759. doi:10.1016/j.annonc.2020.02.011. 17. Mainwaring JM, Walker LM, Robinson JW, et al. The Psychosocial Consequences of Prostate Cancer Treatments on Body Image, Sexuality, and Relationships. Front. Psychol. 2021;12:765315. doi:10.3389/fpsyg.2021.765315. 18. Houédé N, Rébillard X, Bouvet S, et al. Impact on quality of life 3 years after diagnosis of prostate cancer patients below 75 at diagnosis: an observational case-control study. BMC Cancer. 2020;20(1):757. doi:10.1186/s12885-020-07244-y. Obr. 3. Diagnostický algoritmus CaP. Zelenou zvýraznené sú aktuálne body aplikovania Giasay testu na zlepšenie súčasnej diagnostiky a spresnenie indikácie na biopsiu prostaty. Giasay test je využiteľný najmä ako second opinion test pri podozrení na možnú prítomnosť CaP (pomocou rutinných testov ako tPSA, DRE a PSA denzita) alebo ako možnosť monitoringu pacienta počas liečby (pred prostatektómiou) PCa – potvrdená rakovina prostaty, DRE – digital rectal examination/digitálne rektálne vyšetrenie, US – ultrasound/ ultrazvuk, MRI – magnetic resonance imaging/magnetická rezonancia, PET CT – positron emission tomography- -computed tomography/pozitrónová emisná tomografia v kombinácii s počítačovou tomografiou, DX – diagnostika, PI RADS –prostate imaging reporting and data system/systém na vyhodnocovanie dát a zobrazenia prostaty, TRUS – transrectal ultrasonography/transrektálne ultrazvukové vyšetrenie prostaty, Th – terapia, BPH – benign prostatic hyperplasia/benígna prostatická hyperplázia
RkJQdWJsaXNoZXIy NDA4Mjc=